NCT03924856 | Cancer Search

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

A global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.

phase

Phase 3

status

Recruiting

enrollment

870

score

start date

2019-06-13

last updated

2022-01-12

biomarkers

N/A

conditions

Superficial Bladder Urothelial Carcinoma

drugs

cisplatin

gemcitabine

pembrolizumab

primary contact

Toll Free Number

source

clinicaltrials.gov

New York City, New York

New York University Perlmutter Cancer Center ( Site 0008)

Houston, Texas

MD Anderson Cancer Center ( Site 0063)

Indianapolis, Indiana

Indiana University Melvin and Bren Simon Cancer Center ( Site 0004)

Seattle, Washington

Seattle Cancer Care Alliance/Univ of Washington Medical Center ( Site 0033)

Portland, Oregon

Portland VA Medical Center ( Site 0084)

Washington, Washington, D.C.

Georgetown University Medical Center ( Site 0022)

Tulsa, Oklahoma

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0021)

New Orleans, Louisiana

Ochsner Medical Center ( Site 0049)

Cleveland, Ohio

University Hospitals Cleveland Medical Center ( Site 0038)

St. Louis, Missouri

Mercy Hospital Saint Louis ( Site 0064)

Pittsburgh, Pennsylvania

Allegheny General Hospital ( Site 0048)

Orlando, Florida

AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0005)

90 sites
Page 1 of 8

Open Page 2